Grade 3-5 adverse events more than doubled with triplet therapy.
ONCOLOGY
Fully funded by 
Content independently selected
-
Melanoma: questionable benefit for pembrolizumab with dabrafenib/trametinib -
Dabrafenib/trametinib yields 5-year benefit in metastatic melanoma Data from the COMBI-d and COMBI-v trials.
-
Neoadjuvant dabrafenib/trametinib shows benefit in stage III melanoma Data from the phase 2 NeoCombi Trial.
-
Melanoma: age, insurance among factors for surgical delay Analysis of data for over 200,000 patients in the National Cancer Database.
-
ASCO 2019 — Adjuvant ipilimumab yields sustained benefit in stage 3 melanoma Benefit maintained across survival endpoints at 7 years
-
ASCO 2019 — Melanoma: inflammatory markers associated with lower treatment response and survival High CRP and IL-6 expression may prognosticate poorly in stage III-IV melanoma.
-
Swiss study: patients with melanoma at increased risk of additional primary cancers Further evidence for link between melanoma and development of other primary tumors.
-
CML: survivors have increased risk of secondary malignancy Risk pronounced for select neoplasms.
-
Melanoma patients lack confidence in skin self-exams Most are receptive to using digital assist technologies, given sufficient technical support.
-
Advice has been published by the Scottish Medicines Consortium.
-
Meta-analysis: safety of immune checkpoint inhibitors in cancer Large meta-analysis of 125 studies, 20k patients.
-
Melanoma: risk factors differ for lymphatic and hematogenous metastasis Can inform follow-up and adjuvant treatment strategies.
-
Melanoma: 4 factors that predict recurrence A study of 700 patients with high-risk primary melanoma.
-
Sinonasal mucosal melanoma: immunotherapy boosts survival in metastatic disease Largest study to date involves 1874 patients.